Overview

Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy) in Adult Obese or Overweight Subjects

Status:
NOT_YET_RECRUITING

Trial end date:
2027-06-30

Target enrollment:

Participant gender:

Summary

This study is a multicenter, randomized, open-label, parallel-group phase III clinical trial comparing the efficacy and safety of GZR18 Injection and semaglutide (Wegovy) in adult obese or overweight subjects, aiming to evaluate the efficacy and safety of GZR18 Injection in this population.

Phase:

PHASE3

Details

Lead Sponsor:

Gan & Lee Pharmaceuticals.

Treatments:

semaglutide